WO1995022975A1 - Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus - Google Patents
Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus Download PDFInfo
- Publication number
- WO1995022975A1 WO1995022975A1 PCT/US1995/001819 US9501819W WO9522975A1 WO 1995022975 A1 WO1995022975 A1 WO 1995022975A1 US 9501819 W US9501819 W US 9501819W WO 9522975 A1 WO9522975 A1 WO 9522975A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dideoxy
- glucitol
- rsv
- compound
- title compound
- Prior art date
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title claims abstract description 47
- 241000124008 Mammalia Species 0.000 title claims abstract description 9
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 title 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 44
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 7
- 125000002252 acyl group Chemical group 0.000 claims abstract description 5
- 125000003435 aroyl group Chemical group 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 description 92
- 238000005481 NMR spectroscopy Methods 0.000 description 39
- 238000004458 analytical method Methods 0.000 description 38
- 238000000921 elemental analysis Methods 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000003556 assay Methods 0.000 description 35
- 238000002329 infrared spectrum Methods 0.000 description 35
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 32
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 25
- -1 (cyclopropyl) ethyl Chemical group 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 229960000329 ribavirin Drugs 0.000 description 14
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 125000001841 imino group Chemical group [H]N=* 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 6
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 0 *N(C[C@@]([C@]1O)O)[C@](CO)[C@]1O Chemical compound *N(C[C@@]([C@]1O)O)[C@](CO)[C@]1O 0.000 description 5
- AAKDPDFZMNYDLR-UHFFFAOYSA-N N-methyl deoxynojirimycin Natural products CN1CC(O)C(O)C(O)C1CO AAKDPDFZMNYDLR-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 5
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- FTZILAQGHINQQR-UHFFFAOYSA-N 2-Methylpentanal Chemical compound CCCC(C)C=O FTZILAQGHINQQR-UHFFFAOYSA-N 0.000 description 4
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000005916 2-methylpentyl group Chemical group 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- UNNGUFMVYQJGTD-UHFFFAOYSA-N 2-Ethylbutanal Chemical compound CCC(CC)C=O UNNGUFMVYQJGTD-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 125000003713 acetylimino group Chemical group [H]C([H])([H])C(=O)N=[*] 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 3
- 238000003570 cell viability assay Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 3
- JIVGSHFYXPRRSZ-UHFFFAOYSA-N 2,3-dimethoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1OC JIVGSHFYXPRRSZ-UHFFFAOYSA-N 0.000 description 2
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 2
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 2
- 101100331962 Caenorhabditis elegans dnj-2 gene Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 229940124389 anti-rsv drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 2
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- BHQRIPNVIOIWCJ-MVWJERBFSA-N (3r,4r,5s)-2-hexyliminohexane-1,3,4,5-tetrol Chemical compound CCCCCCN=C(CO)[C@@H](O)[C@H](O)[C@H](C)O BHQRIPNVIOIWCJ-MVWJERBFSA-N 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WMXFNCKPYCAIQW-UHFFFAOYSA-N 1,2-dimethoxy-3-methylbenzene Chemical compound COC1=CC=CC(C)=C1OC WMXFNCKPYCAIQW-UHFFFAOYSA-N 0.000 description 1
- XKBQRCUXXCGCMC-UHFFFAOYSA-N 1,4-diphenylbutane-2,3-dione Chemical group C=1C=CC=CC=1CC(=O)C(=O)CC1=CC=CC=C1 XKBQRCUXXCGCMC-UHFFFAOYSA-N 0.000 description 1
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical group CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- NTWBHJYRDKBGBR-UHFFFAOYSA-N 2-ethylbenzaldehyde Chemical compound CCC1=CC=CC=C1C=O NTWBHJYRDKBGBR-UHFFFAOYSA-N 0.000 description 1
- IEEHKTFVUIVORU-UHFFFAOYSA-N 2-methylpropanedioyl dichloride Chemical group ClC(=O)C(C)C(Cl)=O IEEHKTFVUIVORU-UHFFFAOYSA-N 0.000 description 1
- UFIHYFWILAYCSP-UHFFFAOYSA-N 2-methylpropanoyl benzoate Chemical class CC(C)C(=O)OC(=O)C1=CC=CC=C1 UFIHYFWILAYCSP-UHFFFAOYSA-N 0.000 description 1
- PKUPAJQAJXVUEK-UHFFFAOYSA-N 2-phenoxyacetyl chloride Chemical group ClC(=O)COC1=CC=CC=C1 PKUPAJQAJXVUEK-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- DBGTXNFSAQUINV-UHFFFAOYSA-N 2-phenylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(C)C1=CC=CC=C1 DBGTXNFSAQUINV-UHFFFAOYSA-N 0.000 description 1
- LVPGHYVXKUXNQR-UHFFFAOYSA-N 3-iodoheptane Chemical compound CCCCC(I)CC LVPGHYVXKUXNQR-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical group ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 101100331953 Caenorhabditis elegans dnj-1 gene Proteins 0.000 description 1
- 101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- BPVDJXUNJWJXMH-ZGJYDULXSA-N [(2r,3s,4r,5r,6s)-3,4,6-triacetyloxy-5-[(4-methoxyphenyl)methylideneamino]oxan-2-yl]methyl acetate Chemical compound C1=CC(OC)=CC=C1C=N[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O[C@H]1OC(C)=O BPVDJXUNJWJXMH-ZGJYDULXSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical group 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002894 chemical waste Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NALBLJLOBICXRH-UHFFFAOYSA-N dinitrogen monohydride Chemical compound N=[N] NALBLJLOBICXRH-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical group CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical group ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DLRDEMODNIPHMU-UHFFFAOYSA-N tert-butyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OC(C)(C)C)C=C1 DLRDEMODNIPHMU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Definitions
- Respiratory syncytial virus infects the general
- FDA Drug Administration for treatment of repiratory syncytial virus
- RSV repiratory syncytial virus
- FDA Drug Administration for treatment of repiratory syncytial virus
- RSV repiratory syncytial virus
- This nucleoside analog was originally selected as a potential antiviral compound effective against RSV by in vitro
- a method for treating a mammal infected with respiratory syncytial virus comprising administering to the mammal having a disease caused by respiratory syncytial virus (RSV) an RSV inhibitory effective amount of a compound, for an amount of time sufficient to inhibit or eliminate the disease caused by RSV, the compound being selected from the group consisting of l,5-dideoxy-l,5-imino-D-glucitol or an N-alkyl, N-acyl, N-aroyl, N-aralkyl and/or O-acylated derivative thereof.
- RSV respiratory syncytial virus
- the present invention entails administration of an RSV inhibitory effective amount of l,5-dideoxy-l,5-imino-D-glucitol or an N-substituted and/or O-acylated derivative thereof to a mammal infected with respiratory syncytial virus.
- An "RSV inhibitory effective amount" of a compound disclosed herein is an amount of a disclosed compound which inhibits respiratory syncytial virus and does not exhibit adverse toxic effects outweighing the benefit of virus inhibition.
- l,5-dideoxy-l,5-imino-D-glucitol is a six-membered heterocyclic compound having nitrogen in the ring and four hydroxyl groups. It is thus described by a systematic chemical name as a sugar derivative in which the six-membered ring is considered as a mimic of pyranose, with nitrogen instead of oxygen in the ring. It can also be described structurally as a derivative of piperidine.
- the free hydroxyl groups on l,5-dideoxy-l,5-imino-D- glucitol and the N-substituted derivatives thereof may preferably be acylated with up to four, preferably exactly four, O-acyl groups. It is presently preferred to provide the compounds for use in accordance with the present invention as the peracylated derivatives. O-acylated l,5-dideoxy-l,5-imino-D-glucitol and its N-substituted derivatives may be referred to as "prodrugs".
- the O-acyl groups are enzymatically removed to provide the non-O- acylated (i.e., hydroxy-containing N-substituted or unsubstituted 1,5-dideoxy-l,5-imino-D-glucitol compounds) in vivo.
- non-O- acylated i.e., hydroxy-containing N-substituted or unsubstituted 1,5-dideoxy-l,5-imino-D-glucitol compounds
- R 2 , R 3 , R 4 and R 5 may individually be an acyl moiety represented by the formula -C-R 6 wherein R 6 is a linear or branched C,-C 10
- alkyl moiety including but not limited to methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, nonyl, a C j -C 6 cycloalkyl, or a C 4 -C 10 cycloalkylalkyl including but not limited to (cyclopropyl) ethyl, (cyclopropyl)ethyl, (cyclobutyl)ethyl, (cyclopentyl)ethyl, (cyclohexyl)methyl, (cyclohexyl)ethyl and the like.
- the N-alkyl groups may be linear or branched C,-C ⁇ 4 alkyl group, more preferably C ! -C 9 and most preferably a C 4 -C 9 alkyl group including but not limited to methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, nonyl, 2-ethylbutyl and 2-methylpentyl and the like.
- the N-acyl groups include but are not limited to methyl alonyl, ethyl malonyl and the like.
- the N-aralkyl groups may have from about 7 to about 14 carbon atoms and include but are not limited to phenylalkyl moieties wherein the alkyl moiety is a linear or branched Cj-C 8 alkyl, such as benzyl, phenethyl, 3- phenylpropyl, 2-phenylpropyl, butylphenyl, hexylphenyl, 3- phenyloctyl and the like.
- the N-aroyl groups may have from about 7-14 carbons and include but are not limited to phenylacetyl, benzyloxycarbonyl, benzoyl, biphenylacetyl, phenoxyacetyl, chlorophenylacetyl, hydrocinnamoyl, cinnamoyl, and the like, and pyridinylcarbonyl moieties such as nicotinoyl.
- the aryl or aroyl groups can have one or more, preferably 1 to 3, identical or different substituents. Examples of substituents are alkyl or alkoxy having from one to six carbon atoms; halogen such as CI, Br or F; and hydroxyl.
- N-alkyl, N-aralkyl, N- aroyl, N-acyl and/or O-acylated derivatives of 1,5-dideoxy-l,5-imino-D-glucitol The compound l,5-dideoxy-l,5-imino-D-glucitol is alternatively referred to herein as "l-deoxynojirimycin" or simply "DNJ.”
- DNJ is well known and commercially available from a variety of chemical manufacturers, e.g., ICN Bioche icals Inc., Costa Mesa, CA (Cat. # 150819) ; Chemical Dynamics Corporation, South Plainfield, NJ (Cat. # 26-9415-00) .
- Scheme 1 shows a presently preferred method for making N-substituted, O-acylated DNJ wherein R 1 represents N-alkyl or N-aralkyl, and 0(0)-- ⁇ represents the O-acyl moieties defined hereinbefore, the method involving [step (a) ] reductively alkylating DNJ 1 with an alkylaldehyde or arylaldehyde in the presence of hydrogen gas and a catalyst such as palladium/carbon to give N-alkylated DNJ 2, or alternatively alkylating the imino-nitrogen with an alkylhalide or alkyl ester such as an alkyl tosylate, followed by acylation [step (b) ] with the carboxylic acid chloride or carboxylic acid anhydride of an alkyl or aralkyl moiety to provide an O-acylated, N-alkyl (or aralkyl) DNJ 3.
- Suitable alkylaldehydes include but are not limited to butyraldehyde, ethylbutyraldehyde, 2-methylvaleraldehyde, caproaldehyde, and nonylaldehyde.
- Illustrative arylaldehydes are, e.g., benzaldehyde, ethylbenzaldehyde and hydrocinnamaldehyde.
- Suitable alkylating agents include, for example, isopropylbromide, tert-butyl tosylate, 3-heptyliodide, alpha- phenethylmesylate and the like.
- Suitable acid anhydrides include but are not limited to the acetic-, propionic-, butyric-, isobutyric- and benzoic anhydrides.
- Scheme 2 shows a presently preferred method for making N-substituted or unsubstituted, optionally 0- acylated, DNJ derivatives starting from carbobenzyloxy- protected DNJ.
- step c l,5-(Benzyoxycarbonylimino)-1,5- dideoxy-D-glucitol 4 is acylated as described in step (a) to give the compound 5.
- step (d) consists of reductive removal of the carbobenzoxy protecting group by catalytic hydrogenation to give a pera ⁇ ylated DNJ 6.
- Reductive alkylation (e) of 6 as described above for step (a) gives an N-alkyl, O-acylated DNJ derivative 8.
- an amide formation reaction (f) with a peracylated DNJ 6 and a carboxylic acid chloride or carboxylic acid anhydride of an alkyl, aryl or aralkyl moiety in the presence of a base provides an N-acylated, O-acylated DNJ derivative 7.
- the compound 7 can be hydrolyzed with an acid or base to provide the corresponding N-acyl compound 7A.
- the hydrolysis of the ester groups of 7 without hydrolysis of the amide group may be carried out as is well known to those of ordinary skill in the art with reagents such as sodium hydroxide, sodium methoxide, hydrochloric acid and the like.
- Reduction of 7 or 7A to provide 2 or 8 may be accomplished by using, e.g., lithium aluminum hydride.
- Scheme 3 shows a preferred reaction for providing N- substituted, 2,3-O-acylated DNJ deriviatives wherein N- alkyl DNJ 2 is 4-6-O-protected by acetal exchange (h) with dimethoxybenzaldehyde in the presence of acid, followed by acylation (i) and reductive removal of the protecting group (j) essentially as described above for steps (c) and (d) , respectively.
- l,5-dideoxy-l,5-imino- D-glucitol and their N-alkyl, N-acyl and N-aryl, and optionally O-acylated derivatives are the following:
- the foregoing compounds can be demonstrated to have inhibitory activity against respiratory syncytial virus in a tetrazolium based cell viability assay. See Example 44. l,5-dideoxy-l,5-imino-D-glucitol and N-alkyl, N- aralkyl, N-acyl and O-acylated derivatives thereof which have been found to exhibit RSV inhibitor activity, are known to have alpha- and beta-glucosidase inhibitory activity and to inhibit HIV.
- the anti-RSV compounds described herein may be used for administration to a mammalian host infected with respiratory syncytial virus by conventional means, preferably in formulation with pharmaceutically acceptable diluents and carriers.
- the compounds described for use in accordance with the present invention may be used in the free amine form or in their salt form.
- Pharmaceutically acceptable salt derivatives are illustrated, for example, by the hydrochloride salt.
- An "RSV inhibitory effective amount" of a compound disclosed herein is an amount of a disclosed compound which exhibits RSV inhibition, which benefit is not outweighed by adverse toxic effects.
- An RSV inhibitory effective amount of a 1,5-dideoxy-l,5-imino-D-glucitol or N-alkyl, N-aralkyl, N-acyl and/or O-acylated derivative thereof may be an amount which is from about 0.5 milligrams/kilogram body weight/day to about 750 milligrams/kilogram body weight/day, and may be readily determined by a person of ordinary skill in the art based on in vitro efficacy and/or in vivo effect.
- Clinical improvement of a patient being treated in accordance with the method of the present invention may be readily determined by an ordinarily skilled clinician, such as by virological testing or by disappearance of clinically characteristic symptoms of RSV infection.
- a therapeutically effective regimen for treating RSV infection may entail administration of an inhibitory effective amount of an anti-RSV disclosed herein at a rate of 2 to 4 times or more per day for about 7 days to about 14 days or longer.
- the dosage of an anti-RSV compound which is given and/or the length of treatment time may be increased or decreased based on the type and severity of disease, the age (e.g., pediatric v. adult use) and general health of the patient, and like factors of which a clinician of ordinary skill in the art is aware and utilizes in the management of a patient.
- RSV inhibitor compound as disclosed herein may be administered by oral, intravenous, subcutaneous, intramuscular, intranasal or other conventional route which is employed in the art.
- Oral administration of an RSV inhibitory compound in the form of a tablet, capsule, syrup, elixir or the like is presently preferred.
- Suitable formulations of the active compound in combination with pharmaceutically acceptable diluents and carriers in therapeutic dosage form may be readily prepared by reference to general texts in the field of pharmaceutical science such as Remington's Pharmaceutical Sciences, Ed., A. Gennaro, 17th Edition, 1985, Mack Publishing Co., Easton PA.
- Example 2 The title compound of Example 2 (13.417 g, 0.029 moles) was hydrogenated (5 psi, room temperature 2 hrs.) in 250 ml of methanol containing 4% Pd/C (3.0 g) . This mixture was filtered and concentrated in vacuo to give an oil. Chromatography on silica gel gave the title compound as a waxy solid. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C, 4 H 2 ,N0 8 : C, 50.75; H, 6.39; N, 4.23. Found: C, 50.53; H, 6.41; N, 4.14. EXAMPLE 4
- Phenylacetyl chloride (0.23 g, 0.0015 mole) was added to a cold (-76°C, solution of the title compound of Example 3 (0.5 g, 0.0015 mole) in 30 ml tetrahydrofuran. Triethylamine (0.5 ml) was added and the solution stirred for 20 hrs at room temperature. Triethylamine hydrochloride was removed by filtration and the filtrate concentrated in vacuo to give 0.81 g of an oil. Chromatography on silica gel and recrystallizing from ethyl acetate/hexane gave the title product, m.p.
- Acetic anhydride (1.08 g, 0.0106 mole) was added to the title compound of Example 6 (0.50 g, 0.0023 mole) in 5 ml pyridine and stirred for 17 days at room temperature. The product was evaporated under nitrogen gas. The resulting title compound was purified by silica gel chromatography. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C, g H 29 NO g : C, 55.80; H, 7.54; N, 3.62. Found: C, 55.42; H, 7.50; N, 3.72.
- Acetic anhydride (0.69 g, 0.0068 mole) was added to the title compound of Example 9 ( 0.20 g, 0.0011 mole) in 10 ml pyridine and stirred at room temperature for 5 days , The product was concentrated with a gentle flow of nitrogen gas. The residue was dissolved in 25 ml ethyl acetate, washed with water, dried over sodium sulfate, filtered and concentrated to an oil. The product was purified by silica gel chromatography and recrystallized from ethyl acetate-hexane (m.p. 102°C). Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C ⁇ 5 H 23 NO g : C, 52.17; H, 6.71; N, 4.06. Found: C, 52.15; H, 6.72; N, 3.97.
- Example 10 The title compound was prepared by the Method of Example 10 utilizing the product of Example 11 instead of 1,5-(methylimino)-1,5-dideoxy-D-glucitol.
- the structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C 20 H 33 NO g : C, 57.82; H, 8.01; N, 3.37. Found: C, 57.73; H, 7.83; N, 3.36.
- Example 2 To a solution of the title product of Example 1 (2.0 g, 0.0067 mole) in 30 ml pyridine was added isobutyric anhydride (6.4 g, 0.0436 mole) and stirred at room temperature for 6 days. The reaction was poured into 150 ml water, stirred for 20 hrs. and extracted with two portions of ethyl acetate (2 x 100 ml) . The combined organic extracts were washed with water (4 x 75 ml) , dried over sodium sulfate, filtered, and the solvent removed on a rotary evaporator to give an oil. The title compound was purified by silica gel chromatography. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C 30 H 43 NO 10 : C, 62.38; H, 7.50; N, 2.42. Found: C, 62.23; H, 7.60; N, 2.44.
- the title compound was prepared by the Method of Example 7 using n-butyric anhydride instead of acetic anhydride. After purification by silica gel chromatography the product was crystallized from pentane. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C 22 H 45 NO g : C, 62.50; H, 9.08; N, 2.80. Found: C, 62.48; H, 9.12; N, 2.84.
- Example 15 The title compound of Example 15 (2.65 g, 0.0046 mole) was hydrogenated (15 psi, room temperature, 4 hr.) in 100 ml methanol containing 5% Pd/C. This mixture was filtered and concentrated by a rotary evaporator to a solid which was recrystallized from ethyl acetate-hexane (DSC 63°C). Assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C 22 H 37 NO g : C, 59.58; H, 8.41; N, 3.16. Found: C, 59.49; H, 8.46; N, 3.17.
- p-Toluenesulfonic acid monohydrate (10.4 g, 0.055 mole) was added to a solution of dimethoxytoluene (20.8 g, 0.137 mole) in 150 ml of dimethylformamide. After stirring for 3.5 hrs, 1,5-(butylimino)-1,5-dideoxy-D-glucitol (10.0 g, 0.046 mole) was added and the solution was stirred at room temperature for 18 days. The reaction was concentrated on a rotary evaporator. The residue was passed through a column containing Amberlite IRA-400 ion exchange resin with methanol. The eluant was concentrated to a brown oil.
- Acetic anhydride (0.30 g, 0.0029 mole) was added to the product of Example 23 (0.30 g, 0.001 mole) in 10 ml pyridine and stirred for 5 days at room temperature. Water (5 ml) was added and the solution stirred for 1 hr. After removal of the solvent by a rotary evaporator, the product was purified by silica gel chromatography and recrystallized from ethyl acetate-hexane (DSC 126°C). Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for
- the title compound can be prepared by the Method of Example 24 and substituting the product of Example 29 for the product of Example 23.
- the title compound was prepared as a solid by the Method of Example 26 by using 2-methylvaleraldehyde instead of 2-ethylbutyraldehyde in the synthesis reaction. (DSC ca. 89°C.)
- the structure was supported by NMR; infrared spectra and mass spectroscopy.
- Acetic anhydride (0.46 g, 0.0046 mole) was added to the title compound of Example 6 (1.0 g, 0.0046 mole) in 150 ml pyridine cooled to -40°C. by a dry ice/acetone bath. The reaction was allowed to come to room temperature and stirred for 20 hrs. Water (5 ml) was added and the reaction stirred for 1 hr. The solution was concentrated in vacuo to an oil. The title compound was purified by silica gel chromatography to give a solid which was recrystallized from methanol-ethyl acetate (DSC 131°C). The structure assignment was supported by NMR, mass spectroscopy and elemental analysis. Analysis calcd. for C, 2 H 23 N0 5 - 1/3 H20: C, 54.04; H, 8.92; N, 5.25. Found: C, 53.97; H, 9.04; N, 5.53.
- Triethylamine (0.5 ml) was added to a cold (0°C.) solution of l,5-dideoxy-l,5-imino-D-glucitol (0.5 g, 0.0015 mole) and cinnamoyl chloride (0.25 g, 0.0015 mole) in 50 ml tetrahydrofuran. The mixture was allowed to come to room temperature and stirred for 3 days. The reaction mixture was concentrated in vacuo to an oily solid. Ethyl acetate was added to the residue and the solid removed by filtration. After concentrating the filtrate in vacuo, the title compound was purified by silica gel chromatography.
- Example 4 The title compound was prepared by the Method of Example 4 by substituting the title product of Example 19 for the title product of Example 3 in the synthesis reaction. (DSC 96°C. , from ethyl acetatehexane.) The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C 30 H 43 NO 9 : C, 64.15; H, 7.72; N, 2.49. Found: C, 64.15; H, 7.77; N, 2.30.
- Example 19 The title compound was prepared by the Method of Example 19 and substituting the product of Example 41 for the product of Example 15.
- This example describes a tetrazolium-based cell viability assay and demonstrates the anti-RSV activity of various compounds which were prepared as described above.
- the tetrazolium based cell viability assay is based upon the ability of mitochondrial dehydrogenase which is present in viable cells to catalyze the reduction of a yellow tetrazolium salt known as MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenylthtiazolium bromide] to a dark blue/purple formazon product, generally as described by K. Rubino et al., J. Virological Methods, 39, 55-67 (1992)
- Formazan is only slightly soluble in aqueous solutions, and therefore appears as dark cell-associated crystals.
- the crystals may be readily solublized in an organic solvent and the absorbance of the resulting blue/purple solution may be quantified using a multi-well plate spectrophotometer.
- the absorbance values obtained by the method described below have been found to be directly proportional to the number of viable cells present.
- RSV infection results in a marked reduction in cell viability and thus a lowered rate of formazan production.
- the assay method gives a very low absorbance value (practically zero) in wells which contain virus-infected cells and no compound or a compound which lacks anti-RSV activity.
- HEp-2 cells and RSV strain A2 virus which are used in the assay are publicly available and were obtained from the American Tissue Culture Collection.
- HEp-2 cells correspond to ATCC accession no. CCL32; and Respiratory Syncytial Virus, strain A2 corresponds to ATCC accession no. VR-1302.
- Respiratory syncytial virus was grown (i.e., multiplied) and titered in HEp-2 cells.
- the RSV inhibition assay was carried out as follows. The assay was performed in 96 well microtiter plates seeded with 2.5xl0 4 cells per well. To provide a sufficient number of cells to seed the plates, stock cultures of HEp-2 cells were first grown in tissue culture flasks to about 80-100% confluency. The cell layer was washed with room temperature PBS (without calcium and magnesium) and then trypsinized (JRH Biosciences cat. #59- 22877P) in a minimal volume of trypsin solution at 37°C to detach them from the growth surface. Detached cells were resuspended and carefully dispersed in Minimal Essential Medium (MEM) (JRH Biosciences cat. #210-3510) containing 2% FBS (fetal bovine serum) and the concentration of viable cells was determined by trypan blue exclusion.
- MEM Minimal Essential Medium
- Test compound(s) and positive control (ribavirin) were added and serially diluted in the microtiter plate to the desired concentrations (8 replicates/compound/ concentration plus 8 control wells/plate which received no compound) .
- the cell suspension was divided into a first portion to which respiratory syncytial virus (RSV A2) was added at a multiplicity of infection of 1, and a second portion to which no virus was added.
- the virus-infected cell suspension was mixed by low speed vortexing and 100 ⁇ l of the virus-infected cell suspension was immediately added to half of the wells in the 96 well plate (corresponding to 4 replicates of each compound dilution) .
- 100 ⁇ l of the virus-free cell suspension was added to the other half of the wells in the microtiter plate (corresponding to the other 4 replicates for each compound and dilution) .
- a multiplicity of infection equal to 1 was selected based on the observation this concentration of virus is just sufficient to produce a cytopathic effect that essentially eliminated MTT metabolism in infected, untreated cells during the time course of the assay (determined previously by a viral dilution assay) .
- the plates were incubated at 37°C, 5% C0 2 for 5 to 6 days.
- MTT Sigma Chemical Co., St. Louis, MO, Cat. #M21278
- serum free MEM 100 ⁇ l of MTT solution was added to each well and the plates further incubated for 2 hours at 37°C.
- the reaction was stopped by aspiration of the media to chemical waste, being careful not to remove the formazan crystals, and 200 ⁇ l of isopropanol was added to the wells to dissolve the crystals.
- the optical density of the formazan/isopropanol solution from each well was determined using a Dynatech MR5000 multiplate reader at 570 nm with a 630 nm reference.
- the multiplate reader was connected to a computer which received and stored the optical density values on a file server such that the optical density values could be later calculated.
- optical density obtained for each of the four replicate wells per assay condition were averaged and used - 46 - in the following formula derived by N-Ayisi et al., J. Virological Methods, 33, 335-344 (1991), to calculate the % cell protection values for each compound/concentration.
- the % cell protection values and % cytotoxicity values were in turn used to calculate the EC50 and CC50 values.
- the EC50 values were calculated from the % cell protection values obtained.
- the CC50 values were calculated from the % cytotoxicity values obtained.
- the data was best fit to a curve using an adaptation of the Levenberg-Marquardt method of least squares minimization as explained in the book Numerical Recipes in C (Second Edition) by Cambridge University Press, in chapter 15, page 683 in accordance with the following algorithm:
- the nonlinear regression routine used allows for weighted adjustments based on standard deviation of each observed data value.
- this implementation assumes that data errors are normally distributed uniformly across the range of the observed values, so the array of sigmas are just set to 1.0's to effectively remove the weighing. To fit the data to a curve so as to obtain EC50 and
- slope (B) is calculated by applying the LINEST Excel function (Microsoft Excel Version 4.0, function reference p.254, Microsoft Corporation, Redmond, WA) to the sets of predicted valules and predicted concentrations; and C, the ln(EC50) , equals the Y-intercept calculated by applying the LINEST Excel function to the sets of predicted values and predicted concentrations.
- LINEST Excel function Microsoft Excel Version 4.0, function reference p.254, Microsoft Corporation, Redmond, WA
- the predicted concentrations are calculated as In(concentration) .
- the maximum number of iterations performed to achieve convergence is 100, and the convergence criterion relative to Y values is 0.00000001.
- the results of the inhibition assay are set forth in the following table.
- An anti-RSV detection assay was carried out essentially as described in Example 44 except that each of the tested compounds was replenished daily at a single concentration of 200 ⁇ M for 5 days. Because serial dilutions were not used, the antiviral effect (% cell protection) and the cytotoxic effect (% cytotox.) were used directly to obtain the CTI. The results are reported in the following table.
- the compound of Ex. 7 is a prodrug which is enzymatically converted in vivo to the compound of E ⁇ x. 6.
Abstract
A method is provided for treating a mammal infected with respiratory syncytial virus (RSV) comprising administering to the mammal an RSV inhibitory effective amount of a compound or its pharmaceutically acceptable salt of formula (I), wherein R1 is alkyl, aralkyl, aroyl or acyl, and R?2, R3, R4 and R5¿ are H or acyl.
Description
Use of l-deoxynoj1r1myc1n and Its derivatives for treating mammals Infected with respiratory syncytlal virus.
BACKGROUND OF THE INVENTION
Respiratory syncytial virus (RSV) infects the general
10 population each winter. While RSV infection affects and inconveniences otherwise healthy adults with symptoms of the common cold, it produces especially serious symptoms in infants and young children. Essentially all children are infected with respiratory syncytial virus before the
15 age of 3, and RSV can cause severe bronchiolitis or pneumonia, progressing to morbid disease or death in a significant percentage of children. See K. Mclntosh and R. Chanoc , Respiratory Syncytial Virus , Chap. 38, in B. Fields et al. (eds.), Virology, Second Edition, Raven
20 Press, Ltd., New York, NY (1990); W. LaVia et al., J. Pediatrics, 121, 503-510 (1992); M. Stretton et al., Pediatr. Pulmonol. 13, 143-150 (1992); and M. Filippell et al., Infection Control 28, 651-671 (1993).
The only drug to be approved by the U.S. Food and
25 Drug Administration (FDA) for treatment of repiratory syncytial virus (RSV) is ribavirin, 1-beta-D- ribofuranosyl-lH-1,2,4-triazole-3-carboxamide. This nucleoside analog was originally selected as a potential antiviral compound effective against RSV by in vitro
30 testing. Such in vitro tests are useful and virtually the only practical method of initially screening and testing potential anti-RSV drugs. A serious drawback of ribavirin is that it must be inhaled as an aerosol which, for infants and young children, means that it must be
35 administered in an enclosed atmosphere. Moreover, ribavirin has toxic side-effects. Thus, there is a need for improved anti-RSV drugs, especially drugs which do not need to be administered by aerosol and preferably can be delivered orally.
SUMMARY OF THE INVENTION
In accordance with the present invention a method for treating a mammal infected with respiratory syncytial virus comprising administering to the mammal having a disease caused by respiratory syncytial virus (RSV) an RSV inhibitory effective amount of a compound, for an amount of time sufficient to inhibit or eliminate the disease caused by RSV, the compound being selected from the group consisting of l,5-dideoxy-l,5-imino-D-glucitol or an N-alkyl, N-acyl, N-aroyl, N-aralkyl and/or O-acylated derivative thereof. The above-defined compounds have been found to have useful antiviral activity against respiratory syncytial virus.
DETAILED DESCRIPTION OF THE INVENTION
In one of its aspects the present invention entails administration of an RSV inhibitory effective amount of l,5-dideoxy-l,5-imino-D-glucitol or an N-substituted and/or O-acylated derivative thereof to a mammal infected with respiratory syncytial virus. An "RSV inhibitory effective amount" of a compound disclosed herein is an amount of a disclosed compound which inhibits respiratory syncytial virus and does not exhibit adverse toxic effects outweighing the benefit of virus inhibition. l,5-dideoxy-l,5-imino-D-glucitol is a six-membered heterocyclic compound having nitrogen in the ring and four hydroxyl groups. It is thus described by a systematic chemical name as a sugar derivative in which the six-membered ring is considered as a mimic of pyranose, with nitrogen instead of oxygen in the ring. It can also be described structurally as a derivative of piperidine.
1,5-dideoxy-l,5-imino-D-glucitol (R1 = R2 = R3 = R4 = R5 = H)
The free hydroxyl groups on l,5-dideoxy-l,5-imino-D- glucitol and the N-substituted derivatives thereof may preferably be acylated with up to four, preferably exactly four, O-acyl groups. It is presently preferred to provide the compounds for use in accordance with the present invention as the peracylated derivatives. O-acylated l,5-dideoxy-l,5-imino-D-glucitol and its N-substituted derivatives may be referred to as "prodrugs". The O-acyl groups are enzymatically removed to provide the non-O- acylated (i.e., hydroxy-containing N-substituted or unsubstituted 1,5-dideoxy-l,5-imino-D-glucitol compounds) in vivo. M. Bryant et al., 10th International Conference of AIDS, Berlin, June 7-11, 1993, Abstr. No. WS-A11-2. With respect to the O-acyl groups, R2, R3, R4 and R5 may individually be an acyl moiety represented by the formula -C-R6 wherein R6 is a linear or branched C,-C10
0 alkyl moiety including but not limited to methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, nonyl, a Cj-C6 cycloalkyl, or a C4-C10 cycloalkylalkyl including but not limited to (cyclopropyl) ethyl, (cyclopropyl)ethyl, (cyclobutyl)ethyl, (cyclopentyl)ethyl, (cyclohexyl)methyl, (cyclohexyl)ethyl and the like.
The N-alkyl groups may be linear or branched C,-Cι4 alkyl group, more preferably C!-C9 and most preferably a C4-C9 alkyl group including but not limited to methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, nonyl, 2-ethylbutyl and 2-methylpentyl and the like.
The N-acyl groups include but are not limited to methyl alonyl, ethyl malonyl and the like.
The N-aralkyl groups may have from about 7 to about 14 carbon atoms and include but are not limited to phenylalkyl moieties wherein the alkyl moiety is a linear or branched Cj-C8 alkyl, such as benzyl, phenethyl, 3- phenylpropyl, 2-phenylpropyl, butylphenyl, hexylphenyl, 3- phenyloctyl and the like.
The N-aroyl groups may have from about 7-14 carbons and include but are not limited to phenylacetyl, benzyloxycarbonyl, benzoyl, biphenylacetyl, phenoxyacetyl, chlorophenylacetyl, hydrocinnamoyl, cinnamoyl, and the like, and pyridinylcarbonyl moieties such as nicotinoyl. The aryl or aroyl groups can have one or more, preferably 1 to 3, identical or different substituents. Examples of substituents are alkyl or alkoxy having from one to six carbon atoms; halogen such as CI, Br or F; and hydroxyl.
The following reaction schemes describe presently preferred methods for making the N-alkyl, N-aralkyl, N- aroyl, N-acyl and/or O-acylated derivatives of 1,5-dideoxy-l,5-imino-D-glucitol. The compound l,5-dideoxy-l,5-imino-D-glucitol is alternatively referred to herein as "l-deoxynojirimycin" or simply "DNJ." DNJ is well known and commercially available from a variety of chemical manufacturers, e.g., ICN Bioche icals Inc., Costa Mesa, CA (Cat. # 150819) ; Chemical Dynamics Corporation, South Plainfield, NJ (Cat. # 26-9415-00) . In addition, various methods for synthesis of l-deoxynojirimycin and N-
substituted derivatives thereof are disclosed in U.S. Pat. Nos. 4,246,345; 4,266,025; 4,405,714; 4,806,650; and in U.S. Patent Application Serial No. 07/851,818, filed March 16, 1992. The contents of each of the above documents is hereby incorporated by reference into this document.
SCHEME 1
ALDEHYDE H2/CATALYST (a)
OR R<X
ANHYDRIDE + BASE OR
(b) ACID CHLORIDE + BASE
ANHYDRIDE + BASE OR ACID CHLORIDE (f) + BASE
SCHEME 3
ANHYDRIDE + BASE OR ACID CHLORIDE 0) + BASE
Scheme 1 shows a presently preferred method for making N-substituted, O-acylated DNJ wherein R1 represents N-alkyl or N-aralkyl, and 0(0)--^ represents the O-acyl moieties defined hereinbefore, the method involving [step (a) ] reductively alkylating DNJ 1 with an alkylaldehyde or arylaldehyde in the presence of hydrogen gas and a catalyst such as palladium/carbon to give N-alkylated DNJ 2, or alternatively alkylating the imino-nitrogen with an alkylhalide or alkyl ester such as an alkyl tosylate, followed by acylation [step (b) ] with the carboxylic acid chloride or carboxylic acid anhydride of an alkyl or aralkyl moiety to provide an O-acylated, N-alkyl (or aralkyl) DNJ 3. Suitable alkylaldehydes include but are not limited to butyraldehyde, ethylbutyraldehyde, 2-methylvaleraldehyde, caproaldehyde, and nonylaldehyde. Illustrative arylaldehydes are, e.g., benzaldehyde, ethylbenzaldehyde and hydrocinnamaldehyde. Suitable alkylating agents include, for example, isopropylbromide, tert-butyl tosylate, 3-heptyliodide, alpha- phenethylmesylate and the like. Suitable acid anhydrides include but are not limited to the acetic-, propionic-, butyric-, isobutyric- and benzoic anhydrides.
Scheme 2 shows a presently preferred method for making N-substituted or unsubstituted, optionally 0- acylated, DNJ derivatives starting from carbobenzyloxy- protected DNJ. (See, Example 1 herein) . In step c, l,5-(Benzyoxycarbonylimino)-1,5- dideoxy-D-glucitol 4 is acylated as described in step (a) to give the compound 5. Step (d) consists of reductive removal of the carbobenzoxy protecting group by catalytic hydrogenation to give a peraσylated DNJ 6. Reductive alkylation (e) of 6 as described above for step (a) gives an N-alkyl, O-acylated DNJ derivative 8. Alternatively, an amide formation reaction (f) with a peracylated DNJ 6 and a carboxylic
acid chloride or carboxylic acid anhydride of an alkyl, aryl or aralkyl moiety in the presence of a base provides an N-acylated, O-acylated DNJ derivative 7. The compound 7 can be hydrolyzed with an acid or base to provide the corresponding N-acyl compound 7A. The hydrolysis of the ester groups of 7 without hydrolysis of the amide group may be carried out as is well known to those of ordinary skill in the art with reagents such as sodium hydroxide, sodium methoxide, hydrochloric acid and the like. Reduction of 7 or 7A to provide 2 or 8 (not shown) may be accomplished by using, e.g., lithium aluminum hydride.
Scheme 3 shows a preferred reaction for providing N- substituted, 2,3-O-acylated DNJ deriviatives wherein N- alkyl DNJ 2 is 4-6-O-protected by acetal exchange (h) with dimethoxybenzaldehyde in the presence of acid, followed by acylation (i) and reductive removal of the protecting group (j) essentially as described above for steps (c) and (d) , respectively.
Illustrative examples of l,5-dideoxy-l,5-imino- D-glucitol and their N-alkyl, N-acyl and N-aryl, and optionally O-acylated derivatives are the following:
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, 1,5-(Methylimino)-1,5-dideoxy-D-glucitol, 1/5-(Hexylimino)-1,5-dideoxy-D-glucitol,
1,5-(Nonylyli ino)-1,5-dideoxy-D-glucitol, 1,5-(2-Ethylbutylimino)-1,5-dideoxy-D-glucitol, 1,5-(2-Methylpentylimino)-1,5-dideoxy-D-glucitol, 1,5-(Benzyloxycarbonylimino)-1,5-dideoxy-D-glucitol, tetraacetate,
1,5-(Phenylacetylimino)-1,5-dideoxy-D-glucitol, tetraacetate,
1,5-(Benzoylimino)-1,5-dideoxy-D-glucitol, tetraacetate,
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetraacetate,
1,5-(Ethyl malonylimino)-1,5-dideoxy-D-glucitol, tetraacetate, 1,5-(Hexylimino)-1,5-dideoxy-D-glucitol, tetraacetate,
1,5-(Nonylimino)-1,5-dideoxy-D-glucitol, tetraacetate,
1 ,5-(Benzyloxycarbonylimino)-1,5-dideoxy-D-glucitol, tetraisobutyrate,
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetrabutyrate,
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetrapropionate, 1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetrabenzoate, l,5-Dideoxy-l,5-imino-D-glucitol, tetraisobutyrate,
1,5-(Hydrocinnamoylimino)-1,5-dideoxy-D-glucitol, tetraacetate, 1,5-(Methyl malonylimino)-1,5-dideoxy-D-glucitol, tetraacetate,
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetraisobutyrate,
1,5-(Butylimino)-1,5-dideoxy-4R,6-θ-(phenylmethylene) -D-glucitol, diacetate,
1,5-[ (Phenoxymethyl)carbonylimino]-l,5-dideoxy-D- glucitol, tetraacetate, l,5-[ (Ethylbutyl)imino]-l,5-dideoxy-D-glucitol, tetraacetate, 1,5-(Butylimino)-1,5-dideoxy-D-glucitol,
2,3-diacetate,
1,5-(Hexylimino)-1,5-dideoxy-4R,6-0-(phenylmethylene)
-D-glucitol, diacetate,
1,5-(Hexylimino)-1,5-dideoxy-D-glucitol,
2,3-diacetate,
1,5-[ (2-Methylpenty1)imino]-1,5-dideoxy-D-glucitol, tetraacetate, 1,5-(Butylimino)-1,5-dideoxy-D-glucitol, 6-acetate,
1,5-[ (3-Nicotinoyl)imino] -1,5-dideoxy-D-glucitol, tetraacetate,
1,5-(Cinnamoylimino)-1,5-dideoxy-D-glucitol, tetraacetate, 1,5-(Butylimino)-1,5-dideoxy-D-glucitol,
2,3-dibutyrate,
1,5-(Butylimino)-1,5-dideoxy-4R,6-0-(phenylmethylene)
-D-glucitol, 2,3-dibutyrate,
1,5-(Phenylacetylimino)-1,5-dideoxy-D-glucitol, tetraisobutyrate, l,5-[(4-Chlorophenyl)acetylimino]-l,5-dideoxy-D-gluci tol, tetraacetate,
1,5-[ (4-Biphenyl)acetylimino]-1,5-dideoxy-D-glucitol, tetraacetate, 1,5-(Benzyloxycarbonylimino)-1,5-dideoxy-D-glucitol , tetrabutyrate, and
1,5-Dideoxy-l,5-imino-D-glucitol, tetrabutyrate.
The foregoing compounds can be demonstrated to have inhibitory activity against respiratory syncytial virus in a tetrazolium based cell viability assay. See Example 44. l,5-dideoxy-l,5-imino-D-glucitol and N-alkyl, N- aralkyl, N-acyl and O-acylated derivatives thereof which have been found to exhibit RSV inhibitor activity, are known to have alpha- and beta-glucosidase inhibitory activity and to inhibit HIV.
The anti-RSV compounds described herein may be used for administration to a mammalian host infected with respiratory syncytial virus by conventional means,
preferably in formulation with pharmaceutically acceptable diluents and carriers. The compounds described for use in accordance with the present invention may be used in the free amine form or in their salt form. Pharmaceutically acceptable salt derivatives are illustrated, for example, by the hydrochloride salt.
An "RSV inhibitory effective amount" of a compound disclosed herein is an amount of a disclosed compound which exhibits RSV inhibition, which benefit is not outweighed by adverse toxic effects. An RSV inhibitory effective amount of a 1,5-dideoxy-l,5-imino-D-glucitol or N-alkyl, N-aralkyl, N-acyl and/or O-acylated derivative thereof may be an amount which is from about 0.5 milligrams/kilogram body weight/day to about 750 milligrams/kilogram body weight/day, and may be readily determined by a person of ordinary skill in the art based on in vitro efficacy and/or in vivo effect. Clinical improvement of a patient being treated in accordance with the method of the present invention may be readily determined by an ordinarily skilled clinician, such as by virological testing or by disappearance of clinically characteristic symptoms of RSV infection. A therapeutically effective regimen for treating RSV infection may entail administration of an inhibitory effective amount of an anti-RSV disclosed herein at a rate of 2 to 4 times or more per day for about 7 days to about 14 days or longer. The dosage of an anti-RSV compound which is given and/or the length of treatment time may be increased or decreased based on the type and severity of disease, the age (e.g., pediatric v. adult use) and general health of the patient, and like factors of which a clinician of ordinary skill in the art is aware and utilizes in the management of a patient.
An RSV inhibitor compound as disclosed herein may be administered by oral, intravenous, subcutaneous, intramuscular, intranasal or other conventional route which is employed in the art. Oral administration of an RSV inhibitory compound in the form of a tablet, capsule, syrup, elixir or the like is presently preferred. Suitable formulations of the active compound in combination with pharmaceutically acceptable diluents and carriers in therapeutic dosage form may be readily prepared by reference to general texts in the field of pharmaceutical science such as Remington's Pharmaceutical Sciences, Ed., A. Gennaro, 17th Edition, 1985, Mack Publishing Co., Easton PA.
The following non-limiting examples further illustrate the invention.
EXAMPLES
EXAMPLE 1
1,5-(Benzyoxycarbonylimino)-1,5-dideoxy-D-glucitol
Benzyl chloroformate (1.15 g, 0.00674 mole was added to a solution of l,5-dideoxy-l,5-imino-D-glucitol (1.0 g,
0.00613 mole), in 50 ml saturated aqueous sodium hydrogen carbonate and stirred for 20 hrs. at room temperature. The product was extracted into ethyl acetate (3 x 75 ml) , dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to an oil. Chromatography on silical gel gave the title compound (1.2 g) . Structure assignment was supported by NMR and infrared spectra and by elemental analysis. Analysis calcd. for C14HI9N06: C, 56.56; H, 6.44; N, 4.71. Found: C, 56.29; H, 6.62; N, 4.53.
EXAMPLE 2
1,5-(Benzyloxycarbonylimino)-1,5-dideoxy-D-glucitol, tetraacetate
To a solution of the title product of Example 1 (491 g, 1.65 moles) in 5 ml of pyridine was added 2 ml of acetic anhydride. The resulting mixture was stirred for 15 minutes at room temperature and then at reflux for 5 minutes. After cooling, the mixture was poured into 25 ml of ice water and extracted with three portions of ethyl acetate. The combined organic extracts were washed with dilute hydrochloric acid, dried over sodium sulfate, filtered, and the solvant removed on a rotary evaporator. Chromatograghy on silica gel using a gradient of 25 to 100% ethyl acetate-hexane as eluant gave the title compound (510 mg) as an oil. Analysis for C22H27NOι0 (MW 465.46): Calcd. C, 56.76; H, 5.85; N, 3.01. Found: C, 56.72; H, 5.82; N, 3.02.
EXAMPLE 3
1,5-Dideoxy-l,5-imino-D-glucitol, tetraacetate
The title compound of Example 2 (13.417 g, 0.029 moles) was hydrogenated (5 psi, room temperature 2 hrs.) in 250 ml of methanol containing 4% Pd/C (3.0 g) . This mixture was filtered and concentrated in vacuo to give an oil. Chromatography on silica gel gave the title compound as a waxy solid. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C,4H2,N08: C, 50.75; H, 6.39; N, 4.23. Found: C, 50.53; H, 6.41; N, 4.14.
EXAMPLE 4
1,5-(Phenylacetylimino)-1,5-dideoxy-D-glucitol- tetraacetate
Phenylacetyl chloride (0.23 g, 0.0015 mole) was added to a cold (-76°C, solution of the title compound of Example 3 (0.5 g, 0.0015 mole) in 30 ml tetrahydrofuran. Triethylamine (0.5 ml) was added and the solution stirred for 20 hrs at room temperature. Triethylamine hydrochloride was removed by filtration and the filtrate concentrated in vacuo to give 0.81 g of an oil. Chromatography on silica gel and recrystallizing from ethyl acetate/hexane gave the title product, m.p.
98°-100°C. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C22H27N09: C, 58.79; H, 6.05; N, 3.12. Found: C, 58.74; H, 6.12; N, 3.14.
EXAMPLE 5
1,5-(Benzoylimino)-1,5-dideoxy-D-glucitol, tetraacetate
EXAMPLE 6
1,5-(Butylimino)-1,5-dideoxy-D-glucitol
A solution of l,5-dideoxy-l,5-imino-D-glucitol (5.14 g, 0.0315 mole), butyraldehyde (3.35 ml, 0.0380 mole) and Pd black (1 g) in 200 ml methanol was hydrogenated (60 psi/29°C./2l hrs.). After filtering the resulting mixture, the filtrate was concentrated in vacuo to an oil. The title compound was crystallized from acetone and recrystallized from methanol/acetone, m.p. ca. 132°C. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C10H2,NO4: C, 54.78; H, 9.65; N, 6.39. Found: C, 54.46; H, 9.33; N, 6.46.
EXAMPLE 7
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetraacetate
Acetic anhydride (1.08 g, 0.0106 mole) was added to the title compound of Example 6 (0.50 g, 0.0023 mole) in 5 ml pyridine and stirred for 17 days at room temperature. The product was evaporated under nitrogen gas. The resulting title compound was purified by silica gel chromatography. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C,gH29NOg: C, 55.80; H, 7.54; N, 3.62. Found: C, 55.42; H, 7.50; N, 3.72.
EXAMPLE 8
1,5-(Ethyl malonylimino)-1,5-dideoxy-D-glucitol, tetraacetate
Ethyl malonyl chloride (0.5 g, 0.0033 mole) in 10 ml tetrahydrofuran was added to a cold (Oo C.) solution of the title compound of Example 3 (1.0 g, 0.0030 mole) in 30 ml tetrahydrofuran. After stirring for 30 min. a solution of triethylamine (0.67 g, 0.0066 mole) in 10 ml tetrahydrofuran was added. The mixture was allowed to come to room temperature and stirred for 20 hrs. Triethylamine hydrochloride was removed by filtration and the filtrate concentrated in vacuo to give an oil. Chromatography on silica gel gave the title compound as a clear oil. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for
C,9H27NO„: C, 51.23; H, 6.11; N, 3.14. Found: C, 50.99; H, 6.14; N, 3.13.
EXAMPLE 9
1,5-(Methylimino)-1,5-dideoxy-D-glucitol
A solution of 1,5-dideoxy-l,5-imino-D-glucitol (7.5 g, 0.046 mole), formaldehyde (37%, 26.0 g, 0.322 mole) and 5% Palladium black in 300 ml methanol was hydrogenated (60 psi/25°C./20 hrs). After filtering the resulting mixture, the filtrate was concentrated to give a foam. The product was crystallized from methanol-acetone to give a white solid. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C7H,5N04, C 47.45; H, 8.53; N, 7.91. Found: C, 47.24; H, 8.66; N, 7.83.
EXAMPLE 10
1 , 5- (Methylimino) -1 , 5-dideoxy-D-glucitol , tetraacetate
Acetic anhydride (0.69 g, 0.0068 mole) was added to the title compound of Example 9 ( 0.20 g, 0.0011 mole) in 10 ml pyridine and stirred at room temperature for 5 days ,
The product was concentrated with a gentle flow of nitrogen gas. The residue was dissolved in 25 ml ethyl acetate, washed with water, dried over sodium sulfate, filtered and concentrated to an oil. The product was purified by silica gel chromatography and recrystallized from ethyl acetate-hexane (m.p. 102°C). Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for Cι5H23NOg: C, 52.17; H, 6.71; N, 4.06. Found: C, 52.15; H, 6.72; N, 3.97.
EXAMPLE 11
1,5-(Hexylimino) -1,5-dideoxy-D-glucitol
A mixture of l,5-dideoxy-l,5-imino-D-glucitol (0.5 g, 0.0031 moles), caproaldehyde (0.45 g, 0.0045 mole) and 5% Palladium black (0.1 g) in methanol (105 ml) was hydrogenated (5 psi/25°C./5 days). After filtering the resulting mixture, the filtrate was concentrated with a flow of nitrogen to give an oily solid'. The title compound was crystallized from acetone-ethanol, DSC ca. 115°C. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C,2H25N04: C, 58.27; H, 10.19; N, ; 5.66. Found: C, 58.19; H, 10.24; N, 5.65.
EXAMPLE 12
1,5-(Hexylimino)-1,5-dideoxy-D-glucitol, tetraacetate
The title compound was prepared by the Method of Example 10 utilizing the product of Example 11 instead of 1,5-(methylimino)-1,5-dideoxy-D-glucitol. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C20H33NOg: C, 57.82; H, 8.01; N, 3.37. Found: C, 57.73; H, 7.83; N, 3.36.
EXAMPLE 13
1,5-(Nonylimino)-1,5-dideoxy-D-glucitol
A solution of l,5-dideoxy-l,5-imino-D-glucitol (0.5 g, 0.0031 mole); nonyl aldehyde (0.52 g, 0.0037 mole) and 5% Pd black (0.1 g) in methanol (100 ml) was hydrogenated (60 psi/25°C./46 hrs.). After filtering the resulting mixture, the filtrate was concentrated with a gentle flow of nitrogen to an oily solid. This material was stirred with a small amount of acetone and the solid filtered.
Recrystallization from ethanol-acetone gave the title compound, DSC ca. 109°C Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C,5H31N04: C, 62.25; H, 10.80; N, 4.84. Found: C, 62.15; H, 10.86; N, 4.79.
EXAMPLE 14
1,5-(Nonylimino)-1,5-dideoxy-D-glucitol, tetraacetate
The title compound was prepared by the Method of Example 10 utilizing the product of Example 13 instead of 1,5-(methylimino)-1,5-dideoxy-D-glucitol. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C23H39NOg: C, 60.37; H, 8.59; N, 3.06. Found: C, 60.19; H, 7.99; N, 3.12.
EXAMPLE 15
l,5-(Benzyloxlycarbonylimino)-1,5-dideoxy-D-glucitol, tetraisobutyrate
To a solution of the title product of Example 1 (2.0 g, 0.0067 mole) in 30 ml pyridine was added isobutyric anhydride (6.4 g, 0.0436 mole) and stirred at room temperature for 6 days. The reaction was poured into 150 ml water, stirred for 20 hrs. and extracted with two portions of ethyl acetate (2 x 100 ml) . The combined organic extracts were washed with water (4 x 75 ml) , dried over sodium sulfate, filtered, and the solvent removed on a rotary evaporator to give an oil. The title compound was purified by silica gel chromatography. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C30H43NO10: C, 62.38; H, 7.50; N, 2.42. Found: C, 62.23; H, 7.60; N, 2.44.
EXAMPLE 16
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetrabutyrate
EXAMPLE 17
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetrapropionate
CHjCH.COO
The title compound was prepared by the Method of Example 7 substituting propionic anhydride for acetic anhydride. The structure was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C^Ha^Og: C, 59.58; H, 8.41; N, 3.16. Found: C, 59.56; H, 8.68; N, 3.19.
EXAMPLE 18
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetrabenzoate
The title compound was prepared by the Method of Example 7 substituting benzoic anhydride for acetic anhydride. The reaction was allowed to stir at room temperature for 27 days. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C38H37NOg: C, 71.80; H, 5.87; N, 2.20. Found: C, 71.49; H, 5.92; N, 2.24.
EXAMPLE 19
1,5-Dideoxy-l,5-imino-D-glucitol, tetraisobutyrate
The title compound of Example 15 (2.65 g, 0.0046 mole) was hydrogenated (15 psi, room temperature, 4 hr.) in 100 ml methanol containing 5% Pd/C. This mixture was filtered and concentrated by a rotary evaporator to a solid which was recrystallized from ethyl acetate-hexane (DSC 63°C). Assignment was supported by NMR, infrared
spectra and elemental analysis. Analysis calcd. for C22H37NOg: C, 59.58; H, 8.41; N, 3.16. Found: C, 59.49; H, 8.46; N, 3.17.
EXAMPLE 20
1,5-(Hydrocinnamoylimino)-1,5-dideoxy-D-glucitol, tetraacetate
By the method of Example 4 and substituting hydrocinnamoyl chloride for phenylacetyl chloride the title compound was prepared Structure assignment was supported by NMR, infrared spectra and elemental analysis, Analysis calcd. for C^H^NO,: C, 59.60; H, 6.31; N, 3.02. Found: C, 59.49; H, 6.25; N, 3.08.
EXAMPLE 21
1,5-(Methyl malonylimino)-1,5-dideoxy-D-glucitol, tetraacetate
The title compound was prepared by the Method of Example 8 and substituting methyl malonyl chloride for ethyl malonyl chloride. The structure assignment was supported by NMR, infrared spectra and elemental analysis, Analysis calcd. for C,gH25NOn: C, 50.12; H, 5.84; N, 3.25. Found: C, 49.91; H, 5.82; N, 3.13.
EXAMPLE 22
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, tetraisobutyrate
OCOCHfCHj
(CHjhCHCOO,-, OCOCH(CHj)j
I X OCOCH(CHj)2
CH,
The title compound was prepared by the Method of Example 7 and substituting isobutyric anhydride for acetic anhydride, m.p. 59°C. The structure was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C26H45N08: C, 62.50; H, 9.08; N, 2.80. Found: C, 62.43; H, 9.24; N, 2.82.
EXAMPLE 23
1,5-(Butylimino)-1,5-dideoxy-4R,6-0-(phenylmethylene)-D- glucitol
p-Toluenesulfonic acid monohydrate (10.4 g, 0.055 mole) was added to a solution of dimethoxytoluene (20.8 g, 0.137 mole) in 150 ml of dimethylformamide. After stirring for 3.5 hrs, 1,5-(butylimino)-1,5-dideoxy-D-glucitol (10.0 g, 0.046 mole) was added and the solution was stirred at room temperature for 18 days. The reaction was concentrated on a rotary evaporator. The residue was passed through a column containing Amberlite IRA-400 ion exchange resin with methanol. The eluant was concentrated to a brown oil. The title compound was purified by silica gel chromatography and crystallized from ethyl acetate-hexane (DSC 118°C). The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C17H25N04: C, 66.43; H, 8.20; N 4.56. Found: C, 66.38; H, 8.20; N, 4.52.
EXAMPLE 24
1,5-(Butylimino)-1,5-dideoxy-4R,6-0-(phenylmethylene)-D- glucitol, diacetate
Acetic anhydride (0.30 g, 0.0029 mole) was added to the product of Example 23 (0.30 g, 0.001 mole) in 10 ml pyridine and stirred for 5 days at room temperature. Water (5 ml) was added and the solution stirred for 1 hr. After removal of the solvent by a rotary evaporator, the product was purified by silica gel chromatography and recrystallized from ethyl acetate-hexane (DSC 126°C). Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for
C21H29N06: C, 64.43; H, 7.47; N, 3.58. Found: C, 64.39; H, 7.70; N, 3.53.
EXAMPLE 25
1,5-[ (Phenoxymethyl) carbonylimino]-1,5-dideoxy-D-glucitol, tetraacetate
EXAMPLE 26
l,5-[ (2-Ethylbutyl)imino]-1,5-dideoxy-D-glucitol
A solution of l,5-dideoxy-l,5-imino-D-glucitol (0.99 g, 0.0061 mole), 2-ethylbutyraldehyde (0.98 g, 0.0098 mole) and 5% Pd black in methanol (68 ml), tetrahydrofuran (34 ml) and water (17 ml) was hydrogenated (5 psi/25°C./72 hrs.). After filtering the resulting mixture, the filtrate was concentrated to an oily solid. This residue was dissolved in methanol (40 ml) and cooled. The white solid was removed by filtration to give as l,5-dideoxy-l,5-imino-D-glucitol. The filtrate was concentrated to an oil. The product was purified by silica gel chromatography to give a white solid. Recrystallization from methanol-ethyl acetate gave the title compound, DSC ca. 95°C. Structural assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for CI2H25N04: C, 58.27; H, 10.19; N, 5.66. Found: C, 57.89; H, 10.09; N, 5.69.
EXAMPLE 27
l,5-[ (2-Ethylbutyl)imino]-1,5-dideoxy-D-glucitol, tetraacetate
The title compound was prepared by the Method of Example 7 and substituting l,5-[ (2-ethylbutyl)imino]- 1,5-dideoxy-D-glucitol for 1,5-(butylimino)-1,5-dideoxy- D-glucitol. Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C20H33NOg: C, 57.82; H, 8.01; N, 3.37. Found: C, 57.42; H, 7.92; N, 3.31.
EXAMPLE 28
1,5-(Butylimino)-1,5-dideoxy-D-glucitol, 2,3-diacetate
A mixture of the title compound of Example 24 (1.9 g, 0.0049 mole) and 20% Pd black (2.0 g) in methanol, tetrahydrofuran and methanol (6:4:2) was hydrogenated (60
psi/60°C./21 hr.). After filtering the resulting mixture, the filtrate was concentrated in vacuo to an oil. The product was purified by silica gel chromatography. Structure assignment was supported by NMR and elemental analysis. Analysis calcd. for C,4H25N06: C, 55.43; H, 8.31; N, 4.62. Found: C, 55.40; H, 8.38; N, 4.50.
EXAMPLE 29
1,5-(Hexylimino)-1,5-dideoxy-4R,6-0-(phenylmethylene)-D- glucitol
The title compound was prepared by the Method of
Example 23 and substituting the product of Example 11 for 1,5-(butylimino)-1,5-dideoxy-D-glucitol (DSC 101°C.) Structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C,9H29N04: C, 68.03; H, 8.71; N, 4.18. Found: C, 68.04; H, 8.76; N, 4.15.
EXAMPLE 30
1,5-(Hexylimino)-1,5-dideoxy-4R,6-0-(phenylmethylene)-D- glucitol, 2,3-diacetate
The title compound can be prepared by the Method of Example 24 and substituting the product of Example 29 for the product of Example 23.
EXAMPLE 31
1 ,5-(Hexylimino)-1,5-dideoxy-D-glucitol, 2,3-diacetate
The title compound can be prepared by the Method of Example 28 by substituting the product of Example 30 for the product of Example 24 in the synthesis reaction.
EXAMPLE 32
1,5-[ (2-Methylpentyl)imino]-1,5-dideoxy-D-glucitol
The title compound was prepared as a solid by the Method of Example 26 by using 2-methylvaleraldehyde instead of 2-ethylbutyraldehyde in the synthesis reaction. (DSC ca. 89°C.) The structure was supported by NMR; infrared spectra and mass spectroscopy.
EXAMPLE 33
l,5-[ (2-Methylpentyl)imino]-1,5-dideoxy-D-glucitol, tetraacetate
The title compound was prepared by the Method of Example 7 by substituting 1,5-[ (2-Methylpentyl)imino]- 1,5-dideoxy-D-glucitol for 1,5-(butylimino)-1,5-dideoxy- D-glucitol in the synthesis reaction. The structure assignment was supported by CMR and NMR.
EXAMPLE 34
1,5-(Butylimino)-l,5-dideoxy-D-glucitol, 6-acetate
Acetic anhydride (0.46 g, 0.0046 mole) was added to the title compound of Example 6 (1.0 g, 0.0046 mole) in 150 ml pyridine cooled to -40°C. by a dry ice/acetone bath. The reaction was allowed to come to room temperature and stirred for 20 hrs. Water (5 ml) was added and the reaction stirred for 1 hr. The solution was concentrated in vacuo to an oil. The title compound was purified by silica gel chromatography to give a solid which was recrystallized from methanol-ethyl acetate (DSC 131°C). The structure assignment was supported by NMR, mass spectroscopy and elemental analysis. Analysis calcd. for C,2H23N05- 1/3 H20: C, 54.04; H, 8.92; N, 5.25. Found: C, 53.97; H, 9.04; N, 5.53.
EXAMPLE 35
1 , 5- [ ( 3 -Nicot inoy 1 ) imino ] -1 , 5-dideoxy-D-glucitol , tetraacetate
EXAMPLE 36
1,5-(Cinnamoylimino)-l,5-dideoxy-D-glucitol, tetraacetate
Triethylamine (0.5 ml) was added to a cold (0°C.) solution of l,5-dideoxy-l,5-imino-D-glucitol (0.5 g, 0.0015 mole) and cinnamoyl chloride (0.25 g, 0.0015 mole) in 50 ml tetrahydrofuran. The mixture was allowed to come to room temperature and stirred for 3 days. The reaction mixture was concentrated in vacuo to an oily solid. Ethyl acetate was added to the residue and the solid removed by filtration. After concentrating the filtrate in vacuo, the title compound was purified by silica gel chromatography. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for Cy^NO,,: C, 59.86; H, 5.90; N, 3.04. Found: C, 59.66; H, 5.93; N, 2.99.
EXAMPLE 37
1 , 5- (Butylimino) -1 , 5-dideoxy-4R, 6-0- (phenylmethylene) -D- glucitol , 2 , 3 -dibutyrate
The title compound was prepared by the Method of Example 24 by substituting butyric anhydride for acetic anhydride in the synthesis reaction. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C25H37N06: C, 67.09; H, 8.33; N, 3.13. Found: C, 67.05; H, 8.44; N, 3.12.
EXAMPLE 38
1 , 5- (Butylimino) -1 , 5-dideoxy-D-glucitol , 2 , 3 -dibutyrate
The title compound was prepared by the Method of Example 28 by substituting the title compound of Example 37 for the title compound of Example 24. Structure assignment was supported by NMR and elemental analysis. Analysis calcd. for CιgH33N06: C, 60.14; H, 9.25; N, 3.90. Found: C, 59.98; H, 9.38; N, 3.82.
- 40 - EXAMPLE 39
1,5-(Phenylacetylimino)-1,5-dideoxy-D-glucitol, tetraisobutyrate
The title compound was prepared by the Method of Example 4 by substituting the title product of Example 19 for the title product of Example 3 in the synthesis reaction. (DSC 96°C. , from ethyl acetatehexane.) The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C30H43NO9: C, 64.15; H, 7.72; N, 2.49. Found: C, 64.15; H, 7.77; N, 2.30.
EXAMPLE 40
l, 5- [ (4-Chlorophenyl) acetylimino] -l , 5-dideoxy-D-glucitol , tetraacetate
EXAMPLE 41
1,5-(Benzyloxycarbonylimino)-1,5-dideoxy-D-glucitol, tetrabutyrate
The title compound was prepared by the Method of Example 15 by substituting butyric anhydride for isobutyric anhydride in the synthesis reaction. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C30H43NOι0: C, 62.38; H, 7.50; N, 2.42. Found: C, 62.21; H, 7.52; N, 2.42.
975
- 42 - EXAMPLE 42
1,5-Dideoxy-l,5-imino-D-glucitol, tetrabutyrate
The title compound was prepared by the Method of Example 19 and substituting the product of Example 41 for the product of Example 15. The structure assignment was supported by NMR infrared spectra and elemental analysis. Analysis calcd. for C22H37N08: C, 59.58; H, 8.41; N, 3.16. Found: C, 59.46; H, 8.52; N, 3.19.
EXAMPLE 43
1,5-(3-Phenylpropylimino)-1,5-dideoxy-D-glucitol
The title compound was prepared by the method of Example 6 and substituting hydrocinnamaldehyde for butyraldehyde. The structure assignment was supported by NMR, infrared spectra and elemental analysis. Analysis calcd. for C,5H23N04: C, 64.04; H, 8.24; N, 4.98. Found C, 63.66; H, 8.16; N, 4.93.
EXAMPLE 44
RESPIRATORY SYNCYTIAL VIRUS ASSAY
This example describes a tetrazolium-based cell viability assay and demonstrates the anti-RSV activity of various compounds which were prepared as described above. The tetrazolium based cell viability assay is based upon the ability of mitochondrial dehydrogenase which is present in viable cells to catalyze the reduction of a yellow tetrazolium salt known as MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenylthtiazolium bromide] to a dark blue/purple formazon product, generally as described by K. Rubino et al., J. Virological Methods, 39, 55-67 (1992)
Formazan is only slightly soluble in aqueous solutions, and therefore appears as dark cell-associated crystals. The crystals may be readily solublized in an organic solvent and the absorbance of the resulting blue/purple solution may be quantified using a multi-well plate spectrophotometer. The absorbance values obtained by the method described below have been found to be directly proportional to the number of viable cells present. RSV infection results in a marked reduction in cell viability and thus a lowered rate of formazan production. The assay method gives a very low absorbance value (practically zero) in wells which contain virus-infected cells and no compound or a compound which lacks anti-RSV activity. Compounds which inhibit RSV replication should prevent cell death and will therefore result in an increased intensity of color of the formazan solution. The measurement of viral growth as a function of cell viability allows the assay to be used for establishing
levels of compound cytotoxicity in uninfected cells within the same assay. Thus, the assay provides a rapid colorimetric method for measuring RSV specific cytopathic effect. The HEp-2 cells and RSV strain A2 virus which are used in the assay are publicly available and were obtained from the American Tissue Culture Collection. HEp-2 cells correspond to ATCC accession no. CCL32; and Respiratory Syncytial Virus, strain A2 corresponds to ATCC accession no. VR-1302. Respiratory syncytial virus was grown (i.e., multiplied) and titered in HEp-2 cells.
The RSV inhibition assay was carried out as follows. The assay was performed in 96 well microtiter plates seeded with 2.5xl04 cells per well. To provide a sufficient number of cells to seed the plates, stock cultures of HEp-2 cells were first grown in tissue culture flasks to about 80-100% confluency. The cell layer was washed with room temperature PBS (without calcium and magnesium) and then trypsinized (JRH Biosciences cat. #59- 22877P) in a minimal volume of trypsin solution at 37°C to detach them from the growth surface. Detached cells were resuspended and carefully dispersed in Minimal Essential Medium (MEM) (JRH Biosciences cat. #210-3510) containing 2% FBS (fetal bovine serum) and the concentration of viable cells was determined by trypan blue exclusion.
Cell density was adjusted to 2.5 x 105 viable cells/ml by further dilution in MEM + 2% FBS.
Test compound(s) and positive control (ribavirin) were added and serially diluted in the microtiter plate to the desired concentrations (8 replicates/compound/ concentration plus 8 control wells/plate which received no compound) .
The cell suspension was divided into a first portion to which respiratory syncytial virus (RSV A2) was added at
a multiplicity of infection of 1, and a second portion to which no virus was added. The virus-infected cell suspension was mixed by low speed vortexing and 100 μl of the virus-infected cell suspension was immediately added to half of the wells in the 96 well plate (corresponding to 4 replicates of each compound dilution) . 100 μl of the virus-free cell suspension was added to the other half of the wells in the microtiter plate (corresponding to the other 4 replicates for each compound and dilution) . A multiplicity of infection equal to 1 was selected based on the observation this concentration of virus is just sufficient to produce a cytopathic effect that essentially eliminated MTT metabolism in infected, untreated cells during the time course of the assay (determined previously by a viral dilution assay) .
The plates were incubated at 37°C, 5% C02 for 5 to 6 days.
After the incubation period, MTT (Sigma Chemical Co., St. Louis, MO, Cat. #M2128) was dissolved in serum free MEM to give a 3mg/ml solution and 100 μl of MTT solution was added to each well and the plates further incubated for 2 hours at 37°C. The reaction was stopped by aspiration of the media to chemical waste, being careful not to remove the formazan crystals, and 200 μl of isopropanol was added to the wells to dissolve the crystals. The optical density of the formazan/isopropanol solution from each well was determined using a Dynatech MR5000 multiplate reader at 570 nm with a 630 nm reference. The multiplate reader was connected to a computer which received and stored the optical density values on a file server such that the optical density values could be later calculated.
The optical density obtained for each of the four replicate wells per assay condition were averaged and used
- 46 - in the following formula derived by N-Ayisi et al., J. Virological Methods, 33, 335-344 (1991), to calculate the % cell protection values for each compound/concentration. The % cell protection values and % cytotoxicity values were in turn used to calculate the EC50 and CC50 values.
(OP RSV - (ODηmock
% Cell Protection = 1 + x 100 (ODC)mock - (ODC)RSV
% Cytotoxicity = 100
Where (ODT)RSV = optical density in the presence of virus and compound
(ODT)mock = optical density in the absence of virus, but in the presence of compound
(ODC)mock = optical density in the absence of virus and in the absence of compound
(ODC)RSV = optical density in the presence of virus, but in the absence of compound
The EC50 values were calculated from the % cell protection values obtained. The CC50 values were calculated from the % cytotoxicity values obtained. The data was best fit to a curve using an adaptation of the Levenberg-Marquardt method of least squares minimization
as explained in the book Numerical Recipes in C (Second Edition) by Cambridge University Press, in chapter 15, page 683 in accordance with the following algorithm:
y = (D - A)/(l + exp(B*C - B*ln(x)))
where: y = dependent variable (biological response) x — independent variable (concentration of compound tested) A = minimum value of assay B = "slope"
C = ln(EC50) (or ln(CC50)) D = maximum value of assay
* represents multiplication.
The nonlinear regression routine used allows for weighted adjustments based on standard deviation of each observed data value. However, this implementation assumes that data errors are normally distributed uniformly across the range of the observed values, so the array of sigmas are just set to 1.0's to effectively remove the weighing. To fit the data to a curve so as to obtain EC50 and
CC50 values, first A is set to equal a value which is 0.99
* the minimum observed assay value; D is set to equal 1.01
* the maximum observed assay value; slope (B) is calculated by applying the LINEST Excel function (Microsoft Excel Version 4.0, function reference p.254, Microsoft Corporation, Redmond, WA) to the sets of predicted valules and predicted concentrations; and C, the ln(EC50) , equals the Y-intercept calculated by applying the LINEST Excel function to the sets of predicted values
and predicted concentrations. In the event that the obtained results show D or A to differ significantly from 100% or 0% respectively, curve fits were repeated with the value for D fixed to 100% and/or the value of A fixed to 0%, in which case the program calculates only the slope and the ln(EC50) values using the fixed minimum and maximum provided.
The predicted values are calculated as follows:
min + (max - min)
(1 + exp(slope * ln(EC50) - slope * ln(observed value)))
The predicted concentrations are calculated as In(concentration) .
The maximum number of iterations performed to achieve convergence is 100, and the convergence criterion relative to Y values is 0.00000001. The results of the inhibition assay are set forth in the following table.
INHIBITION OF RSV (Ribavirin Control)
COMPOUND HEp-2
OF EXAMPLE -CC50 -EC50
NO. Solvent (μM) (βM) ASSAY CONDITIONS CTI'
Ex. 6 DMSO 100.3 24.7 5 day assay, drug added on day 1 only 4.1
Ex. 6 PBS 76245.6* 247.8* 5 day assay, drug added on day 1 only 275.5
Ex. 6 DMSO 155.5 58.1 5 day assay, drug added on day 1 only 2.7
Ex. 6 PBS 9397.1* 431.1 6 day assay, drug added on day 1 only 21.8
Ex. 6 DMSO 365.1* 250.2* 6 day assay, drug added on day 1 only 1.5
Ex. 6 PBS # 625.5* 5 day assay, drug added on day 1 only #
Ex. 6 PBS # 45.0 5 day assay, drug replenished daily #
Ex. 6 PBS # 683.0* 5 day assay, drug added on day 1 only #
Ex. 6 PBS # 184.6 5 day assay, drug replenished on day 3 #
Ex. 6 PBS # 228.3* 5 day assay, drug added on day 1 only # ribavirin water 20.4 2.6 5 day assay, drug replenished on day 3 7.9 ribavirin water 38.3 6.3 5 day assay, drug added on day 1 only 6.1 ribavirin water 32.432 6.470 5 day assay, drug added on day 1 only 5.0 ribavirin water 62.809 2.495 5 day assay, drug added on day 1 only 25.2 ribavirin water 179.304 19.089 6 day assay, drug added on day 1 only 9.39 ribavirin water 52.394 2.844 5 day assay, drug added on day 1 only 18.4 ribavirin water 40.0 0.1 5 day assay, drug replenished daily 644.9
* extrapolated
# no apparent toxicity, unable to extrapolate
EC50
' CTI (cytotherapeutic index) =
CC50
EXAMPLE 45
An anti-RSV detection assay was carried out essentially as described in Example 44 except that each of the tested compounds was replenished daily at a single concentration of 200 μM for 5 days. Because serial dilutions were not used, the antiviral effect (% cell protection) and the cytotoxic effect (% cytotox.) were used directly to obtain the CTI. The results are reported in the following table.
INHIBITION OF RSV (Ribavirin Control)
COMPOUND OF % CELL % CELL PROTECTION EXAMPLE NO. SOLVENT PROTECTION % CYTOTOXICITY % CYTOTOXICITY
EX. 43 PBS 102 10 10
EX. 6 PBS 54 17 3.1
EX. 7 PBS 6 11 0.5
Ribavirin water 106 65 1.6
The compound of Ex. 7 is a prodrug which is enzymatically converted in vivo to the compound of EΞx. 6.
Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.
Claims
1. A method for treating a mammal infected with respiratory syncytial virus (RSV) comprising administering to the mammal an RSV inhibitory effective amount of a compound or its pharmaceutically acceptable salt of the formula
wherein R1 is selected from the group consisting of H, linear or branched C,-CI4 alkyl; C7-C,4 aroyl; C7-C,4 aralkyl, wherein the aryl moiety of the aralkyl or aroyl is optionally substituted with from 1 to 3 substituents selected from the group of C,-C6 alkyl, C,-C6 alkoxy, hydroxy, Cl, Br and F; and wherein R2, R3, R4 and R5 are independently selected from the group consisting of H and acyl group of the formula 0
-C-R° wherein R° is a linear or branched C,-CJ0 alkyl, a C3-C7 cycloalkyl, or a C4-C,0 (cycloalkyl)alkyl moiety.
2. A method according to Claim 1 wherein R1 is selected from the group of C,-C9 alkyl and C7-CI4 aryl; and Rj, R3, R4 and R5 are each H or C,-C,0 acyl.
3. A method according to Claim 2 wherein R1 is C4-C9 alkyl.
4. A method according to Claim 2 wherein R1 is C7-Cι4 aralkyl.
5. A method according to Claim 3 wherein R1 is n-butyl.
6. A method according to Claim 4 wherein R1 is 3- phenylpropyl.
7. A method according to Claim 1 wherein the RSV inhibitory effective amount of compound is administered orally.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU18760/95A AU1876095A (en) | 1994-02-25 | 1995-02-21 | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20153794A | 1994-02-25 | 1994-02-25 | |
| US08/201,537 | 1994-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1995022975A1 true WO1995022975A1 (en) | 1995-08-31 |
Family
ID=22746235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/001819 WO1995022975A1 (en) | 1994-02-25 | 1995-02-21 | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US5622972A (en) |
| AU (1) | AU1876095A (en) |
| WO (1) | WO1995022975A1 (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998002161A1 (en) * | 1996-07-15 | 1998-01-22 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| WO1999024401A1 (en) * | 1997-11-10 | 1999-05-20 | G.D. Searle & Co. | Use of alkylated iminosugars to treat multidrug resistance |
| WO1999040916A1 (en) * | 1998-02-12 | 1999-08-19 | G.D. Searle & Co. | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| US6515028B1 (en) | 1999-02-12 | 2003-02-04 | G.D. Searle & Co. | Glucamine compounds for treating hepatitis virus infections |
| US6545021B1 (en) | 1999-02-12 | 2003-04-08 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| AU761748B2 (en) * | 1997-12-11 | 2003-06-12 | Chancellor, Masters And Scholars Of The University Of Oxford, The | Inhibition of membrane-associated viral replication |
| US6689759B1 (en) | 1998-02-12 | 2004-02-10 | G. D. Searle & Co. | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy |
| EP1714676A2 (en) * | 1998-02-12 | 2006-10-25 | G.D. Searle LLC. | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| WO2007140184A2 (en) | 2006-05-24 | 2007-12-06 | United Therapeutics Corporation | Deoxynojirimycin and d-arabinitol analogs and methods of using |
| US7612093B2 (en) | 1997-02-14 | 2009-11-03 | United Therapeutics Corporation | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy |
| EP2473493A1 (en) * | 2009-09-04 | 2012-07-11 | United Therapeutics Corporation | Methods of treating poxviral infections |
| CN102625796A (en) * | 2009-09-04 | 2012-08-01 | 联合治疗公司 | Methods of treating Orthomyxoviral infections |
| EP2932982A1 (en) | 2005-05-17 | 2015-10-21 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| CN111904959A (en) * | 2020-08-21 | 2020-11-10 | 牡丹江医学院 | Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia |
| WO2022040741A1 (en) * | 2020-08-26 | 2022-03-03 | COVIRIX Medical Pty Ltd | Glucosidase inhibitors for the treatment and prevention of pulmonary infections |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| CN100364534C (en) * | 1998-02-12 | 2008-01-30 | G.D.瑟尔公司 | Use of n-substituted-1,5-di deoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| ES2302697T3 (en) * | 1999-08-10 | 2008-08-01 | The Chancellor, Masters And Scholars Of The University Of Oxford | LONG CHAIN N-ALQUILIC COMPOUNDS AND OXA DERIVATIVES OF THE SAME AND USE AS ANTIVIRAL COMPOSITIONS. |
| US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| CN1422156A (en) * | 2000-02-14 | 2003-06-04 | 法马西亚公司 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| US20050256168A1 (en) * | 2004-04-28 | 2005-11-17 | Block Timothy M | Compositions for oral administration for the treatment of interferon-responsive disorders |
| BRPI0613222A2 (en) * | 2005-06-08 | 2010-12-28 | Amicus Therapeutic Inc | method for purifying a nitrogen-containing raw sugar and method for purifying crude d-1-deoxygalactonojirimycin (dgj) |
| GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| JP2009545621A (en) * | 2006-08-02 | 2009-12-24 | ユナイテッド セラピューティクス コーポレーション | Liposome treatment of viral infections |
| KR20090057035A (en) * | 2006-08-21 | 2009-06-03 | 유나이티드 세러퓨틱스 코오포레이션 | Combination therapy for treatment of viral infections |
| WO2008122082A1 (en) * | 2007-04-04 | 2008-10-16 | Brc Ip Pty Ltd | Brain function parameter measurement system and method |
| US8097728B2 (en) * | 2007-04-30 | 2012-01-17 | Philadelphia Health & Education Corporation | Iminosugar compounds with antiflavirus activity |
| CA2719567A1 (en) * | 2008-03-26 | 2009-10-01 | University Of Oxford | Endoplasmic reticulum targeting liposomes |
| JP5600329B2 (en) * | 2009-02-23 | 2014-10-01 | ユナイテッド セラピューティクス コーポレーション | Methods for treating iminosugars and viral diseases |
| EP2400843B1 (en) * | 2009-02-24 | 2015-11-11 | United Therapeutics Corporation | Iminosugars and methods of treating arenaviral infections |
| WO2010109330A2 (en) * | 2009-03-27 | 2010-09-30 | University Of Oxford | Cholesterol level lowering liposomes |
| US8426445B2 (en) * | 2009-06-12 | 2013-04-23 | United Therapeutics Corporation | Iminosugars and methods of treating bunyaviral and togaviral diseases |
| EP2473046B1 (en) * | 2009-09-04 | 2014-10-22 | United Therapeutics Corporation | Iminosugars for their use in the treatment of filoviral diseases |
| JP2013512945A (en) | 2009-12-07 | 2013-04-18 | ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード | N-substituted deoxynojirimycin compounds for use in the inhibition of osteoclastogenesis and / or osteoclast activation |
| US10144727B2 (en) | 2013-09-16 | 2018-12-04 | Emergent Virology Llc | Deoxynojirimycin derivatives and methods of their using |
| US10428022B2 (en) | 2014-11-05 | 2019-10-01 | Emergent Virology Llc | Iminosugars useful for the treatment of viral diseases |
| US20190282558A1 (en) * | 2016-05-16 | 2019-09-19 | Emergent Virology Llc | Methods of Treating Zika Virus Infection |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| CN116077494A (en) * | 2023-01-11 | 2023-05-09 | 黑龙江中医药大学 | Pharmaceutical composition for treating respiratory syncytial virus and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2834122A1 (en) * | 1978-08-03 | 1980-02-14 | Bayer Ag | METHOD FOR PRODUCING 6-AMINO-6-DESOXY-L-SORBOSE |
| DE2853573A1 (en) * | 1978-12-12 | 1980-07-03 | Bayer Ag | PREPARATION OF N-SUBSTITUTED DERIVATIVES OF L-DESOXYNOJIRIMYCIN |
| DE3038901A1 (en) * | 1980-10-15 | 1982-05-06 | Bayer Ag, 5090 Leverkusen | METHOD FOR PRODUCING N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN |
| DE3611841A1 (en) * | 1986-04-09 | 1987-10-15 | Bayer Ag | METHOD FOR PRODUCING 1-DESOXYNOJIRIMYCIN AND ITS N-DERIVATIVES |
| US5144037A (en) * | 1988-11-03 | 1992-09-01 | G. D. Searle & Co. | 1,5-dideoxy-1,5-imino-d-glucitol derivatives |
| US5221746A (en) * | 1988-11-03 | 1993-06-22 | G. D. Searle & Co. | 1,5-dideoxy-1,5-imino-D-glucitol derivatives |
| US5003072A (en) * | 1988-11-03 | 1991-03-26 | G. D. Searle & Co. | 1,5-dideoxy-1,5-imino-D-glucitol derivatives |
| US4957926A (en) * | 1988-12-22 | 1990-09-18 | Monsanto Company | Method of treating herpesviruses |
| US5030638A (en) * | 1990-02-26 | 1991-07-09 | G. D. Searle & Co. | Method of antiviral enhancement |
-
1995
- 1995-02-21 WO PCT/US1995/001819 patent/WO1995022975A1/en active Application Filing
- 1995-02-21 AU AU18760/95A patent/AU1876095A/en not_active Abandoned
-
1996
- 1996-01-26 US US08/585,603 patent/US5622972A/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| "Antiviral activity of some natural and synthetic sugar analogues", FEBS LETT., vol. 291, no. 2, pages 199 - 202 * |
| "Inhibition of HIV and SIV infectivity by blockade of alpha-glucosidase activity", VIROLOGY, vol. 181, no. 1, pages 180 - 92 * |
| "Inhibitory effect of novel 1-deoxynojirimycin derivatives on HIV-1 replication", AIDS, vol. 4, no. 110, pages 975 - 9 * |
| 7TH INT.CONFERENCE ON ANTIVIRAL RESEARCH, CHARLESTON, USA, FEB.27-MAR 45, 1994; ANTIVIRAL RESEARCH, vol. 23, no. spl.1, pages 133. * |
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017122133A (en) * | 1996-07-15 | 2017-07-13 | ジェンザイム コーポレーション | Deoxynojirimycin derivatives and uses of said derivatives as glucosylceramidase inhibitors |
| JP2000516577A (en) * | 1996-07-15 | 2000-12-12 | ユニフェルシテイト ファン アムステルダム | Deoxynojirimycin derivatives and use of the derivatives as glucosylceramidase inhibitors |
| US6177447B1 (en) | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| JP2016056203A (en) * | 1996-07-15 | 2016-04-21 | Genzyme Corp | Deoxynojirimycin derivatives and uses of said derivatives as glucosylceramidase inhibitors |
| JP2014024857A (en) * | 1996-07-15 | 2014-02-06 | Genzyme Corp | Deoxy-nojirimycin derivative and use of derivative as glucosylceramidase inhibitor |
| WO1998002161A1 (en) * | 1996-07-15 | 1998-01-22 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| US7612093B2 (en) | 1997-02-14 | 2009-11-03 | United Therapeutics Corporation | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy |
| WO1999024401A1 (en) * | 1997-11-10 | 1999-05-20 | G.D. Searle & Co. | Use of alkylated iminosugars to treat multidrug resistance |
| US6225325B1 (en) | 1997-11-10 | 2001-05-01 | G.D. Searle & Company | Use of alkylated iminosugars to treat multidrug resistance |
| AU761748B2 (en) * | 1997-12-11 | 2003-06-12 | Chancellor, Masters And Scholars Of The University Of Oxford, The | Inhibition of membrane-associated viral replication |
| US6809083B1 (en) | 1998-02-12 | 2004-10-26 | Richard A. Mueller | Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections |
| EP1714676A2 (en) * | 1998-02-12 | 2006-10-25 | G.D. Searle LLC. | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| EP1714676A3 (en) * | 1998-02-12 | 2006-11-15 | G.D. Searle LLC. | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| US6689759B1 (en) | 1998-02-12 | 2004-02-10 | G. D. Searle & Co. | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy |
| AU762125B2 (en) * | 1998-02-12 | 2003-06-19 | G.D. Searle & Co. | Use of (N)-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| WO1999040916A1 (en) * | 1998-02-12 | 1999-08-19 | G.D. Searle & Co. | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| US6545021B1 (en) | 1999-02-12 | 2003-04-08 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| US6747149B2 (en) | 1999-02-12 | 2004-06-08 | G. D. Searle & Co. | Glucamine salts for treating hepatitis virus infections |
| US6515028B1 (en) | 1999-02-12 | 2003-02-04 | G.D. Searle & Co. | Glucamine compounds for treating hepatitis virus infections |
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| EP3441090A1 (en) | 2005-05-17 | 2019-02-13 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| EP2932982A1 (en) | 2005-05-17 | 2015-10-21 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| EP2023927A2 (en) * | 2006-05-24 | 2009-02-18 | United Therapeutics Corporation | Deoxynojirimycin and d-arabinitol analogs and methods of using |
| JP2013129662A (en) * | 2006-05-24 | 2013-07-04 | United Therapeutics Corp | Deoxynojirimycin and d-arabinitol analog and method of use |
| EP2023927A4 (en) * | 2006-05-24 | 2013-04-10 | United Therapeutics Corp | Deoxynojirimycin and d-arabinitol analogs and methods of using |
| US8975280B2 (en) | 2006-05-24 | 2015-03-10 | The Chancellor, Masters And Scholars Of The University Of Oxford | Deoxynojirimycin and D-arabinitol analogs and methods of using |
| WO2007140184A2 (en) | 2006-05-24 | 2007-12-06 | United Therapeutics Corporation | Deoxynojirimycin and d-arabinitol analogs and methods of using |
| CN102625796B (en) * | 2009-09-04 | 2015-03-11 | 联合治疗公司 | Methods of treating Orthomyxoviral infections |
| EP2473482A4 (en) * | 2009-09-04 | 2013-01-16 | United Therapeutics Corp | Methods of treating orthomyxoviral infections |
| EP2473493A4 (en) * | 2009-09-04 | 2013-01-09 | United Therapeutics Corp | Methods of treating poxviral infections |
| CN102625796A (en) * | 2009-09-04 | 2012-08-01 | 联合治疗公司 | Methods of treating Orthomyxoviral infections |
| EP2473493A1 (en) * | 2009-09-04 | 2012-07-11 | United Therapeutics Corporation | Methods of treating poxviral infections |
| CN111904959A (en) * | 2020-08-21 | 2020-11-10 | 牡丹江医学院 | Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia |
| WO2022040741A1 (en) * | 2020-08-26 | 2022-03-03 | COVIRIX Medical Pty Ltd | Glucosidase inhibitors for the treatment and prevention of pulmonary infections |
| AU2021332085B2 (en) * | 2020-08-26 | 2022-12-08 | COVIRIX Medical Pty Ltd | Glucosidase inhibitors for the treatment and prevention of pulmonary infections |
Also Published As
| Publication number | Publication date |
|---|---|
| US5622972A (en) | 1997-04-22 |
| AU1876095A (en) | 1995-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5622972A (en) | Method for treating a mammal infected with respiratory syncytial virus | |
| CA2002106C (en) | O-acylated derivatives of 1,5-dideoxy-1, 5-imino-d-glucitol | |
| EP0284621B1 (en) | New psychostimulant agent | |
| AU707144B2 (en) | Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect | |
| US3793365A (en) | Amino acid derivatives | |
| US5310745A (en) | Antiviral compounds | |
| CN102595895A (en) | Iminosugars and methods of treating filoviral diseases | |
| CA2059063C (en) | Novel antiviral compounds | |
| JP5404607B2 (en) | Aniline derivative having anti-RNA virus action | |
| US6020344A (en) | Enzyme inhibitors and methods of use | |
| AU748836B2 (en) | Methods for preventing and treating pestivirus infection and associated diseases | |
| AU603373B2 (en) | Pharmaceutical composition for protection of brain cells | |
| EP1699778B1 (en) | (4-phenylpiperazin-1-yl)acylpiperidine derivatives, preparation thereof and application of same in therapeutics | |
| US3867425A (en) | Substituted benzyl carbazic acid esters | |
| WO1991018886A1 (en) | Compounds for the treatment of age-related memory impairment and other cognitive disorders | |
| JPH01193264A (en) | 1-((5-(4-substituted-1-piperadinyl)methyl)-pyrrol -2-yl or fran-2-yl)methyl 2-piperadines effective for treatment of schizophrenia | |
| US4876268A (en) | Antiviral compounds and use thereof | |
| CA2251060C (en) | Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action | |
| CA2002105C (en) | Dideoxy-l-arabinitol derivatives as antiviral compounds | |
| US3856838A (en) | Beta-naphthyl alkylidene carbazic acid esters | |
| JPH07504405A (en) | Method for delaying AIDS in HIV individuals by administration of substituted azaspiran compounds | |
| US3930003A (en) | Coumarine derivatives and process for the preparation thereof | |
| HU217298B (en) | Substituted aminoalkylaminopyridil-methylthiobenzimidazole- and -imidazo [5,4-b]piridine derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds | |
| AU2002356351A1 (en) | New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds | |
| CA1074700A (en) | Method and compositions of thiazolylphenylguanidines as antirhinovirus agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |